Ryan C. Heniford/LinkedIn
Oct 14, 2025, 05:26
Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
Ryan C. Heniford, Director of Global Business Development and Technical Marketing at Evonik, shared a post on LinkedIn:
”Today is World Thrombosis Day! A reminder that thrombosis prevention isn’t just about medication, it’s also about smarter medical devices.
That’s where Evonik’s Endexo technology comes in.
It’s an innovative passive surface modification that makes catheter surfaces inherently more biocompatible — no coatings, no drugs, no leaching.
Key benefits at a glance:
- Up to 99 % reduction in thrombus accumulation
- Less protein and platelet adhesion → reduced clot risk
- Lower friction for smoother handling and less trauma
- Durable performance because Endexo® is part of the polymer itself
On World Thrombosis Day, it’s worth remembering that every thrombus prevented is a patient protected — and that innovation in materials science plays a crucial role in that.”
Stay updated with Hemostasis Today.
-
Feb 27, 2026, 18:30Sanjeev Saksena: From Isolated Case Reports to Clinical Evidence for Post-Ablation Myocardial Ischemia
-
Feb 27, 2026, 18:21Priya Prasad: Can Money Buy Blood?
-
Feb 27, 2026, 18:19Trulee Cardona: Hemophilia Care in Uzbekistan and Why It Matters
-
Feb 27, 2026, 18:19Bartosz Hudzik: Do Elevated Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Otherwise Healthy Women?
-
Feb 27, 2026, 18:14Mohamed Sikkander Abdul Razak: Factor XIa Inhibitors Show Promise With Lower Bleeding Risk
-
Feb 27, 2026, 18:09Hariom Rajput: Early Recognition and Prevention of Deep Vein Thrombosis
-
Feb 27, 2026, 18:08Karen Fahey: What If the Blood Products You Rely On Weren’t Safe?
-
Feb 27, 2026, 17:46Perla Bandini: Whole-Exome Sequencing Unveils Suspected Primary Hemostasis Disorders
-
Feb 27, 2026, 17:44Ekaterina Balaian: Exploring Fostamatinib Use in APS Patients with Thrombocytopenia